Nordic Nanovector AS

Nordic Nanovector AS is a privately held company established in 2009. The company develops novel anticancer therapeutics based on The Norwegian Radium Hospital and Nordic Nanovector's own innovative research on tumor targeted antibody based nanovector. By applying a beta-particle emitting radionuclide conjugated to a tumor seeking carrier, malignant metastasized tumors can be irradiated with minimal damage to nearby healthy normal tissue. This technology aims to prolong survival and improve the quality of life of people who suffer from hematologic cancer in particular non-Hodgkin Lymphoma. Compared with current antibody based therapies on non-Hodgkin Lymphoma which uses the antigen CD20 as the target, Nordic Nanovector' lead compound Betalutin targets the CD37 antigen that is expressed on almost all B-cell in non-Hodgkin Lymphoma. Thus, the large number of patients who eventually fail CD20 directed therapies could benefit from CD37 directed therapies. The leading candidate, Betalutin is currently in clinical phase 2 and is planning to start pivotal phase 2 at the end of 2017. Nordic Nanovector was listed in 2015 at the Oslo Stock Exchange. Birk Venture made the first investment in the company in 2010. Go to website Back to menu